ABOUT EVENT
In an era defined by rapid advancements, the Innovation in Obesity Therapeutics Summit – West Coast stands out as a pivotal event dedicated exclusively to latest and greatest research and development across the field of obesity.
Set against the backdrop of a booming market with the obesity landscape undergoing a seismic shift, driven by the GLP-1 surge that has catalyzed a wave of innovation and investment. As the industry evolves, staying ahead of the curve is essential for leaders looking to navigate this dynamic environment.
2024 Program Highlights
Examining Areas of Improvement in the Current Standard of Care to Unlock the Next Generation of Obesity Therapeutics dive into the areas where there is room for improvement, whether that be no non-responders, duration of efficacy, reduced side effects or even improved fat mass to lean mass ratio.
Raising the Bar to Bariatric (BMS) - Examining Novel Drug Classes & Combinations with The Potential to Surpass Current Efficacy Benchmarks explore novel drug classes and combinations with the potential to exceed the current weight loss benchmark, crucial for providing more effective, accessible treatment options for a broader patient population.
Quality of Weight Loss Over Quantity of Weight Loss: Highlighting Novel Therapeutic Approaches with the Propensity to Mitigate Muscle Loss Side Effects in Weight Loss examine the implications of cyclic weight loss and its implications on muscle loss, examine novel therapies that prevent muscle loss ensures healthier, more sustainable weight reduction, enhancing long-term health.
Delving into Durability: Exploring Innovative Approaches in Obesity Therapeutic Development to Sustain & Maintain Weight Loss explores strategies that enhance the durability of therapeutic effects, ensuring sustained weight loss and improved patient outcomes. From combination therapies to genetic targeting ultimately elevating the standard of care in obesity management.
Target Product Profile: Exploring Innovation in Drug Profiles from Alternative Administration Routes to Novel Modalities delves into innovative solutions that streamline peptide production and explores alternative modalities that bypass these challenges altogether. By investigating new small molecules and oral agents, identify more efficient and cost-effective pathways to obesity treatment, enhancing accessibility and scalability of next-generation therapeutics.
Exploring Novel Targets Beyond GLP-1: Pioneering Advances to Transform the Standards of Obesity Care uncover novel biological targets beyond GLP-1 that hold the promise to revolutionize obesity therapeutics, investigate cutting-edge research on alternative receptors, signalling pathways, and metabolic processes, to identify breakthrough targets that can deliver superior efficacy, reduced side effects, and enhanced patient outcomes.
Are you at the forefront of this new wave of therapeutics?
This summit is your opportunity to engage with industry leaders, uncover pioneering research and evaluate the entirety of the obesity landscape, ensure you are at the heart of this transformative movement in the obesity industry.